1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Meningitis - Pipeline Review, H1 2020, provides an overview of the Meningitis (Infectious Disease) pipeline landscape.
"Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life threatening.Viral meningitis is not life-threatening and the people affected with this can be cured and recover quickly, but bacterial meningitis is serious and life-threatening. There are three major bacteria which lead to bacterial meningitis. Neisseria meningitides are one of these, and causes meningococcal meningitis.
Researchers have identified 13 major serogroups of N. meningitides, out of which the majority of cases are from one of five serogroups: A, B, C, Y and W-135. Drugs and vaccines are available to treat the serogroups AC, C, ACWY, and A. There are also vaccines available to prevent meningitis caused by serogroups A, C, Y, W-135. There are no vaccines or drugs available for the prevention and treatment of meningococcal meningitis caused by serogroup B.
This represents a major unmet need in the market. Pneumococcal meningitis is another major bacterial cause of meningitis, caused by the bacteria streptococcus pneumonia, while haemophilius influenza is the third, and causes meningitis in infants. Approximatiely 44-46% cases of bacterial meningitis have all of the following three symptoms - severe headache, nuchal ridgidity ((inability to flex the neck forward passively due to increased neck muscle tone and stiffness) and altered mental status. Out of this triad of symptoms severe headache is the most common and occurs in 90% of the cases. If nove of the above mentioned symptoms are present, then occurrence of bacterial meningitis is least likely.Other clinical feature include photophobia (fear of bright light), phonophobia (fear of loud noises). In small children above symptoms are difficult to spot. Vague symptoms like irritability and unwell appearance are more common in them. In infants up to 6 months bulging of the fontanelle (soft spot on baby’s head) may be visible. Other less severe illnesses like extreme cold, abnormality in skin color and leg pain may also be distinguishing features for meningitis."
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Meningitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Meningitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Meningitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 4, 5 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.
Meningitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Meningitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Meningitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Meningitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Meningitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Meningitis (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Meningitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Meningitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Meningitis - Overview
- Meningitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Meningitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Meningitis - Companies Involved in Therapeutics Development
- CanSino Biologics Inc
- Chongqing Zhifei Biological Products Co Ltd
- Eubiologics Co Ltd
- FUJIFILM Toyama Chemical Co Ltd
- Liaoning Cheng Da Biotechnology Co Ltd
- Linnaeus Bioscience Inc
- Matinas BioPharma Holdings Inc
- Mycovia Pharmaceuticals Inc
- Olymvax Biopharmaceuticals Inc
- Pneumagen Ltd
- TGV Therapeutics
- Yisheng Biopharma Co Ltd
- Meningitis - Drug Profiles
- Product Description
- Mechanism Of Action
- R&D Progress
- Product Description
- Mechanism Of Action
- R&D Progress
- Product Description
- Mechanism Of Action
- R&D Progress
- amphotericin B - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CSB-015 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- EUC-004 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- flucytosine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Haemophilus influenzae B vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- meningitis vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- meningococcal [serotypes A and C] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- meningococcal [serotypes A, C] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- MYC-053 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Neumifil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- pneumococcal [serotype 4, 6A] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule for Cryptococcal Meningitis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit GWT1 for Cryptococcal Meningitis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- T-2307 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- VT-1129 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- VT-1598 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Meningitis - Dormant Projects
- Meningitis - Discontinued Products
- Meningitis - Product Development Milestones
- Featured News & Press Releases
- Feb 19, 2020: Matinas BioPharma announces DSMB approval to commence part 2 of EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis
- Oct 14, 2019: Matinas BioPharma initiates EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of fungal cryptococcal meningitis
- Oct 07, 2019: Matinas BioPharma receives orphan drug designation from U.S. FDA for MAT2203 for the treatment of cryptococcosis
- Jul 25, 2019: Matinas BioPharma receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis
- Jun 03, 2019: Matinas BioPharma to present on MAT2203 at the 9th Annual LD Micro Invitational
- May 28, 2019: Matinas BioPharma announces publication of MAT2203 Preclinical Cryptococcal Meningitis data in the American Society for Microbiology Journal, mBio
- May 01, 2019: Matinas BioPharma selected to present at the BioNJ Ninth Annual BioPartnering Conference
- Dec 20, 2018: Matinas BioPharma to present data on MAT2203 at Biotech Showcase 2019
- Aug 08, 2017: Matinas BioPharma Reaffirms Clinical and Regulatory Strategy to Advance MAT2203
- Jun 02, 2017: Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis
- May 30, 2017: Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology's ASM Microbe 2017 Conference
- Jun 16, 2016: Clinical Trial of Phase III of Group A and Group C Meningococcal Conjugate vaccine Phase III Clinical Trial Initiated
- Jun 01, 2016: Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis
- Sep 16, 2015: FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis
- Jun 29, 2015: Olymvax obtains Chinese approval for clinical trials of Meningococcal conjugate vaccine
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact
- Disclaimer
List of Tables
- Number of Products under Development for Meningitis, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Meningitis - Pipeline by CanSino Biologics Inc, H1 2020
- Meningitis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
- Meningitis - Pipeline by Eubiologics Co Ltd, H1 2020
- Meningitis - Pipeline by FUJIFILM Toyama Chemical Co Ltd, H1 2020
- Meningitis - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, H1 2020
- Meningitis - Pipeline by Linnaeus Bioscience Inc, H1 2020
- Meningitis - Pipeline by Matinas BioPharma Holdings Inc, H1 2020
- Meningitis - Pipeline by Mycovia Pharmaceuticals Inc, H1 2020
- Meningitis - Pipeline by Olymvax Biopharmaceuticals Inc, H1 2020
- Meningitis - Pipeline by Pneumagen Ltd, H1 2020
- Meningitis - Pipeline by TGV Therapeutics, H1 2020
- Meningitis - Pipeline by Yisheng Biopharma Co Ltd, H1 2020
- Meningitis - Dormant Projects, H1 2020
- Meningitis - Dormant Projects, H1 2020 (Contd..1), H1 2020
- Meningitis - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Meningitis, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- CanSino Biologics Inc
- Chongqing Zhifei Biological Products Co Ltd
- Eubiologics Co Ltd
- FUJIFILM Toyama Chemical Co Ltd
- Liaoning Cheng Da Biotechnology Co Ltd
- Linnaeus Bioscience Inc
- Matinas BioPharma Holdings Inc
- Mycovia Pharmaceuticals Inc
- Olymvax Biopharmaceuticals Inc
- Pneumagen Ltd
- TGV Therapeutics
- Yisheng Biopharma Co Ltd
